Allarity Therapeutics Inc. has announced an amendment to its Sales Agreement with Ascendiant Capital Markets, LLC, increasing the total amount of common stock it may offer and sell to $24,000,000. This update, detailed in Supplement No. 10 to the Prospectus Supplement dated March 19, 2024, follows the company's public float exceeding $75.0 million on May 2, 2024, which lifted the previous sales limitation under General Instruction I.B.6 of Form S-3. As of May 14, 2024, Allarity Therapeutics has already sold 17,959,714 shares for gross proceeds of $21,995,067. The new prospectus supplement, dated May 15, 2024, allows for the sale of additional common stock up to the new limit, inclusive of the gross proceeds already obtained through the Sales Agreement.

Allarity Therapeutics Inc. has announced an amendment to its Sales Agreement with Ascendiant Capital Markets, LLC, increasing the total amount of common stock it may offer and sell to $24,000,000. This update, detailed in Supplement No. 10 to the Prospectus Supplement dated March 19, 2024, follows the company's public float exceeding $75.0 million on May 2, 2024, which lifted the previous sales limitation under General Instruction I.B.6 of Form S-3. As of May 14, 2024, Allarity Therapeutics has already sold 17,959,714 shares for gross proceeds of $21,995,067. The new prospectus supplement, dated May 15, 2024, allows for the sale of additional common stock up to the new limit, inclusive of the gross proceeds already obtained through the Sales Agreement.